Evaluation of tissue and circulating mir-21 as potential biomarker of response to chemoradiotherapy in rectal cancer

Susana Ourô, Cláudia Mourato, Marisa P. Ferreira, Diogo Albergaria, André Cardador, Rui E. Castro, Rui Maio, Cecília M.P. Rodrigues

Research output: Contribution to journalArticlepeer-review

Abstract

Response to chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (RC) is quite variable and it is urgent to find predictive biomarkers of response. We investigated miR-21 as tissue and plasma biomarker of response to CRT in a prospective cohort of RC patients; The expression of miR-21 was analyzed in pre-and post-CRT rectal tissue and plasma in 37 patients with RC. Two groups were defined: Pathological responders (TRG 0, 1 and 2) and non-responders (TRG 3). The association between miR-21, clinical and oncological outcomes was assessed; miR-21 was upregulated in tumor tissue and we found increased odds of overexpression in pre-CRT tumor tissue (OR: 1.63; 95% CI: 0.40–6.63, p = 0.498) and pre-CRT plasma (OR: 1.79; 95% CI: 0.45–7.19, p = 0.414) of non-responders. The overall recurrence risk increased with miR-21 overexpression in pre-CRT tumor tissue (HR: 2.175, p = 0.37); Significantly higher miR-21 expression is observed in tumor tissue comparing with non-neoplastic. Increased odds of non-response is reported in patients expressing higher miR-21, although without statistical significance. This is one of the first studies on circulating miR-21 as a potential biomarker of response to CRT in RC patients.

Original languageEnglish
Article number246
JournalPharmaceuticals
Volume13
Issue number9
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Biomarkers
  • Chemoradiotherapy
  • MiR-21
  • Rectal cancer
  • Therapy response
  • Tumor regression grade

Fingerprint

Dive into the research topics of 'Evaluation of tissue and circulating mir-21 as potential biomarker of response to chemoradiotherapy in rectal cancer'. Together they form a unique fingerprint.

Cite this